Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near New Haven, CT

130 studies for Breast Cancer are recruiting at 402 sites within 50 miles of New Haven, Connecticut, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near New Haven.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near New Haven

Showing the 50 nearest of 130 studies.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Yale University (New Haven, CT); Yale-New Haven Hospital North Haven Medical Center (North Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    29 sites within 50 mi
  2. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Center/Yale-New Haven Hospital (New Haven, CT); Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    27 sites within 50 mi
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale University (New Haven, CT); Yale-New Haven Hospital North Haven Medical Center (North Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    26 sites within 50 mi
  4. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Yale University (New Haven, CT); Yale-New Haven Hospital Saint Raphael Campus (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    22 sites within 50 mi
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale University (New Haven, CT); Yale-New Haven Hospital North Haven Medical Center (North Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  6. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale University (New Haven, CT); Yale-New Haven Hospital North Haven Medical Center (North Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    16 sites within 50 mi
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Center/Yale-New Haven Hospital (New Haven, CT); Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    15 sites within 50 mi
  8. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    NCT04893109

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale Cancer Center at Yale University School of Medicine (New Haven, CT); Smilow Cancer Hospital Care center at North Haven (North Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  9. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    NCT06377852

    • Phase 3
    • Ages 60 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Hospital - Yale New Haven Health (New Haven, CT); Yale University/Yale Cancer Center/Yale School of Medicine (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 50 mi
  10. QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

    NCT06551116

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale Cancer Center (New Haven, CT); Yale-New Haven Hospital North Haven Medical Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 50 mi
  11. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    NCT07578116

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Center/Yale-New Haven Hospital (New Haven, CT); Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 50 mi
  12. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    NCT07062965

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Hospital - Yale New Haven Health (New Haven, CT); Smilow Cancer Hospital - North Haven (North Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  13. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Hospital at Yale New Haven (New Haven, CT); New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2) (Port Jefferson Station, NY)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  14. Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    NCT04606446

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Smilow Cancer Hospital Phase 1 Unit (New Haven, CT); Smilow Cancer Hospital at Yale - New Haven (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  15. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    NCT05232916

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Yale Cancer Center - Smilow Cancer Hospital (New Haven, CT); Stony Brook University Cancer Center (Stony Brook, NY)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    NCT06103864

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (New Haven, CT); Research Site (Stony Brook, NY)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    NCT06324357

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale University School of Medicine (New Haven, CT); New York Cancer & Blood Specialists (Shirley, NY)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale Cancer Center ( Site 0053) (New Haven, CT); University of Connecticut Health Center ( Site 0128) (Farmington, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Yale New Haven Hospital- Yale Cancer Center (New Haven, CT); Stony Brook University Cancer Center (Stony Brook, NY)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  21. The Cancer of the Pancreas Screening-5 CAPS5)Study

    NCT02000089

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  22. Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

    NCT03463954

    • Interventional
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  23. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  24. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    NCT04787042

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  25. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    NCT05216432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  26. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    NCT05315700

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

    NCT05768932

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale New Haven Hospital (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. Study of AVZO-021 in Patients With Advanced Solid Tumors

    NCT05867251

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Avenzo Therapeutics Recruiting Site (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    NCT05902988

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    NCT05983432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University, Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

    NCT05989347

    • Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Yale Cancer Center Smilow Cancer Hospital (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    NCT06172478

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Optimizing Surgical Decisions in Young Adults With Breast Cancer

    NCT06275126

    • Interventional
    • Ages 18 to 44 years
    • Sex: Female

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    NCT06395519

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University, Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. Pre-Operative Window of ET to Inform RT Decisions (POWER II)

    NCT06507618

    • Phase 3
    • Ages 65 years and older
    • Sex: Female

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    NCT06533826

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

    NCT06551220

    • Observational
    • Ages 18 to 80 years
    • Sex: Female

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

    NCT06582615

    • Interventional
    • Ages 40 to 65 years
    • Sex: Female

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    NCT06638307

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Comprehensive Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

    NCT06657222

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

    NCT06749210

    • Phase 2
    • Ages 40 years and older
    • Sex: All

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. Trial of Trastuzumab Deruxtecan in Previously Treated HER2

    NCT06750484

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. A Study of PHST001 in Advanced Solid Tumors

    NCT06840886

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

    NCT06888388

    • Observational
    • Ages 18 to 90 years
    • Sex: Female

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

    NCT06917313

    • Phase 2
    • Ages 18 years and older
    • Sex: Female
    • Accepts healthy volunteers

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. Circulating Tumor DNA

    NCT06923527

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

    NCT06953882

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. Saci Nivo Rela for TNBC

    NCT06963905

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers

    Nearest site: Yale University (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale-New Haven Hospital-Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    NCT06993844

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Yale University, Yale Cancer Center (New Haven, CT)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.